Abstract

Incretin-based therapies have fundamentally transformed the clinical landscape for the management of type 2 diabetes mellitus (T2DM) and obesity. These innovative pharmacological interventions leverage the intricate physiological actions of endogenous incretin hormones to restore glucose homeostasis, modulate appetite, and induce sustainable weight loss. This comprehensive report delves into the historical context and groundbreaking discovery of incretin hormones, meticulously details their diverse physiological roles, and critically evaluates the evolution and mechanisms of various pharmacological agents that target these crucial pathways. Furthermore, it explores their extensive clinical applications, critically assesses their efficacy and safety profiles, and outlines the promising future directions in this rapidly evolving and highly impactful therapeutic domain.

1. Introduction

The escalating global epidemics of type 2 diabetes mellitus (T2DM) and obesity represent monumental public health challenges, profoundly impacting patient morbidity, mortality, and healthcare economies worldwide. T2DM, characterized by insulin resistance and progressive pancreatic β-cell dysfunction, affects hundreds of millions globally, often leading to severe microvascular and macrovascular complications. Concurrently, obesity, defined by excessive body fat accumulation, has reached pandemic proportions, serving as a primary driver for T2DM, cardiovascular diseases, certain cancers, and numerous other debilitating conditions. The complex interplay between these two chronic diseases underscores the urgent need for highly effective and multifaceted therapeutic strategies.

For decades, conventional treatments for T2DM primarily focused on improving insulin sensitivity, enhancing insulin secretion through sulfonylureas, or providing exogenous insulin. While impactful, these approaches often came with limitations such as hypoglycemia risk, weight gain, and progressive loss of β-cell function. Similarly, obesity management largely relied on lifestyle modifications, which, despite their importance, frequently yield suboptimal long-term weight loss for many individuals. Surgical interventions, while highly effective, are invasive and not universally applicable. This context set the stage for a profound paradigm shift in metabolic disease management, heralded by the advent of incretin-based therapies.

Incretin hormones, a group of gastrointestinal peptides, emerged from fundamental research into the physiological responses to nutrient ingestion. Their discovery illuminated a powerful, glucose-dependent regulatory system for insulin secretion and glucagon suppression, offering a novel target for pharmacological intervention. The therapeutic journey began with the identification of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as key mediators of the ‘incretin effect’ – the phenomenon where oral glucose elicits a greater insulin response than an equivalent intravenous glucose load. Harnessing this natural physiological mechanism has led to the development of several classes of drugs, including dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 receptor agonists (GLP-1 RAs), and most recently, multi-receptor agonists targeting combinations of GLP-1, GIP, and glucagon receptors. These latter agents, exemplified by tirzepatide and retatrutide, represent the pinnacle of current incretin science, offering unprecedented levels of glycemic control and weight loss, thereby ushering in a new era of metabolic medicine with profound implications for personalized and highly effective therapeutic options for T2DM and obesity.

2. Discovery and Physiological Roles of Incretin Hormones

The concept of an ‘incretin effect’ first emerged in the early 20th century, with initial observations suggesting that oral glucose stimulated a greater insulin response than intravenous glucose. However, it was not until the latter half of the century that the specific gastrointestinal hormones mediating this effect began to be identified and characterized. The two primary incretin hormones, GLP-1 and GIP, are central to the physiological regulation of glucose homeostasis and nutrient metabolism.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2.1. Glucagon-Like Peptide-1 (GLP-1)

2.1.1. Discovery and Secretion

GLP-1 was discovered in the 1980s as a product of the proglucagon gene, primarily synthesized and secreted by enteroendocrine L-cells, which are predominantly located in the distal ileum and colon, but also found to a lesser extent in the jejunum. Its secretion is robustly stimulated within minutes of nutrient ingestion, particularly in response to carbohydrates (monosaccharides and disaccharides) and fats, as well as protein hydrolysis products like amino acids. This rapid post-prandial release ensures that GLP-1 is present to amplify the insulin response precisely when it is most needed to manage incoming glucose. The secretion is triggered by direct contact of nutrients with L-cells, as well as through neural and paracrine mechanisms involving various gut peptides and neurotransmitters.

2.1.2. Mechanisms of Action

GLP-1 exerts its multifaceted effects by binding to the GLP-1 receptor (GLP-1R), a G-protein coupled receptor expressed in a wide range of tissues, including pancreatic β-cells, α-cells, the brain, stomach, heart, and kidney.

• Enhancement of Glucose-Dependent Insulin Secretion: This is the hallmark effect of GLP-1. In pancreatic β-cells, GLP-1R activation leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) through the activation of adenylate cyclase. Elevated cAMP, in turn, activates protein kinase A (PKA) and exchange protein activated by cAMP 2 (EPAC2). These pathways amplify glucose-stimulated insulin secretion by increasing calcium influx and exocytosis of insulin granules. Crucially, this effect is glucose-dependent, meaning GLP-1 only enhances insulin secretion when blood glucose levels are elevated (typically above 3.5-5.5 mmol/L), significantly reducing the risk of hypoglycemia compared to sulfonylureas. Beyond immediate insulin release, GLP-1 also promotes β-cell proliferation, inhibits β-cell apoptosis, and improves β-cell sensitivity to glucose, contributing to the preservation of β-cell mass and function.

• Inhibition of Glucagon Release: GLP-1 effectively suppresses glucagon secretion from pancreatic α-cells, particularly in the presence of elevated glucose. This action reduces hepatic glucose production (gluconeogenesis and glycogenolysis), thereby lowering blood glucose levels. The mechanism involves direct GLP-1R activation on α-cells and indirect effects mediated by intra-islet insulin and somatostatin secretion. Like its effect on insulin, glucagon suppression is also glucose-dependent, ensuring that glucagon release is not excessively inhibited during states of hypoglycemia, thus preserving counter-regulatory mechanisms.

• Delayed Gastric Emptying: GLP-1 slows the rate at which food empties from the stomach into the small intestine. This effect is mediated primarily through vagal nerve activation and direct effects on gastric smooth muscle. By slowing gastric emptying, GLP-1 dampens post-prandial glucose excursions, reduces the speed of nutrient absorption, and contributes to an enhanced sense of fullness.

• Appetite Regulation and Satiety: GLP-1 acts on specific receptors in the central nervous system (CNS), particularly in the hypothalamus (e.g., arcuate nucleus) and brainstem (e.g., nucleus tractus solitarius), to reduce food intake and promote satiety. This effect is mediated by both direct action on neuronal GLP-1Rs and by vagal afferent pathways relaying signals from the gut to the brain. GLP-1 not only reduces the quantity of food consumed but also diminishes hedonic aspects of eating, contributing to sustainable weight loss.

• Cardiovascular Effects: Research has uncovered significant cardioprotective effects of GLP-1. These include improvements in endothelial function, reductions in systemic blood pressure (through vasodilation and natriuresis), anti-inflammatory actions, and direct effects on the myocardium, leading to improved cardiac function and reduced myocardial ischemia. These benefits contribute to the observed reduction in major adverse cardiovascular events (MACE) in clinical trials.

• Renal Effects: GLP-1 RAs have also shown renoprotective effects, including reductions in albuminuria, improvements in glomerular filtration rate, and anti-inflammatory and anti-fibrotic actions within the kidney, independent of glycemic control.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2.2. Glucose-Dependent Insulinotropic Polypeptide (GIP)

2.2.1. Discovery and Secretion

GIP, initially termed Gastric Inhibitory Polypeptide due to its weak inhibitory effect on gastric acid secretion at supraphysiological doses, was later renamed Glucose-dependent Insulinotropic Polypeptide to reflect its primary physiological role. It is secreted by enteroendocrine K-cells, which are predominantly located in the duodenum and jejunum, the proximal segments of the small intestine. GIP secretion is rapidly stimulated by the presence of nutrients, particularly fats (triglycerides) and carbohydrates (glucose), in the upper gut. Its post-prandial release typically peaks earlier than GLP-1, reflecting the earlier absorption of nutrients in the proximal intestine.

2.2.2. Mechanisms of Action

GIP exerts its effects through the GIP receptor (GIPR), another G-protein coupled receptor found on pancreatic β-cells, adipocytes, bone cells, and in the brain.

• Enhancement of Glucose-Dependent Insulin Secretion: Similar to GLP-1, GIP is a potent stimulator of glucose-dependent insulin secretion from pancreatic β-cells. GIPR activation also increases intracellular cAMP, leading to augmented insulin release. While the insulinotropic effect of GIP is robust in healthy individuals, it is often impaired in patients with T2DM, a phenomenon known as GIP resistance. However, pharmacological agonism of the GIPR can still elicit significant insulin release and metabolic benefits in T2DM, particularly when combined with GLP-1 agonism.

• Influence on Fat Metabolism and Adipogenesis: GIP receptors are abundant on adipocytes. GIP promotes energy storage by enhancing fatty acid synthesis (lipogenesis) and triglyceride accumulation in adipose tissue. It also stimulates lipoprotein lipase activity, which facilitates the uptake of circulating triglycerides into fat cells. While this might seem counterproductive for weight loss, GIP also plays a role in healthy adipose tissue expansion, potentially mitigating lipotoxicity in other organs and improving insulin sensitivity in the long term. This nuanced role makes GIP agonism an interesting component in multi-receptor therapies.

• Role in Bone Formation: GIP receptors are expressed in osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). GIP has been shown to stimulate bone formation and inhibit bone resorption, suggesting a potential role in maintaining bone density and health. This indicates a broader physiological impact beyond glucose and lipid metabolism.

• Other Roles: GIP also has mild effects on gastric motility and may play a role in central appetite regulation, although these effects are generally less pronounced than those of GLP-1.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2.3. Glucagon

Glucagon, though often viewed as a counter-regulatory hormone to insulin, is increasingly recognized for its complex interplay with incretins, particularly in the context of multi-receptor agonists. It is a peptide hormone produced by the pancreatic α-cells.

2.3.1. Production and Regulation

Glucagon secretion is primarily stimulated by hypoglycemia, which triggers its release to raise blood glucose. It is also stimulated by amino acids (e.g., after a protein-rich meal) to prevent hypoglycemia that might otherwise occur from amino acid-stimulated insulin release. Conversely, hyperglycemia, insulin, and GLP-1 all suppress glucagon secretion.

2.3.2. Mechanisms of Action

Glucagon exerts its effects by binding to the glucagon receptor (GCGR), a G-protein coupled receptor primarily expressed in the liver, but also in the kidney, heart, and adipose tissue.

• Stimulation of Hepatic Glucose Production: This is glucagon’s most critical function. It potently stimulates gluconeogenesis (synthesis of glucose from non-carbohydrate precursors) and glycogenolysis (breakdown of stored glycogen) in the liver. These processes rapidly release glucose into the bloodstream, counteracting hypoglycemia. Enzymes such as glucose-6-phosphatase and glycogen phosphorylase are key targets.

• Lipolysis: Glucagon stimulates the breakdown of triglycerides in adipose tissue, releasing free fatty acids and glycerol. These fatty acids can be used as an energy source by various tissues and as substrates for gluconeogenesis in the liver.

• Other Effects: Glucagon also has positive inotropic and chronotropic effects on the heart and can increase energy expenditure.

2.3.3. Dysregulation in T2DM

In T2DM, α-cell function is often dysregulated, leading to hyperglucagonemia (excessive glucagon secretion) despite elevated glucose levels. This inappropriate glucagon secretion significantly contributes to persistent hyperglycemia by driving excessive hepatic glucose output, even in the fasting state and post-prandially. Therefore, therapies that can modulate glucagon secretion or its action are highly relevant for T2DM management.

3. Pharmacological Agents Targeting Incretin Pathways

The short half-life of native GLP-1 (minutes, due to rapid degradation by DPP-4 enzyme) and the observed GIP resistance in T2DM patients presented initial challenges for direct therapeutic use. However, sustained research efforts led to the development of various pharmacological strategies to overcome these limitations and harness the incretin system’s full potential.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.1. GLP-1 Receptor Agonists (GLP-1 RAs)

GLP-1 RAs are synthetic analogues that mimic the actions of endogenous GLP-1 but are designed to be resistant to DPP-4 degradation and/or have prolonged half-lives, allowing for less frequent administration. They directly activate GLP-1 receptors, leading to robust and sustained incretin effects.

• Exenatide (Byetta, Bydureon): Derived from exendin-4, a peptide found in the saliva of the Gila monster lizard, exenatide was the first GLP-1 RA approved for T2DM. Its initial formulation (Byetta) was short-acting, requiring twice-daily injections. A long-acting, once-weekly formulation (Bydureon) was later developed using microsphere technology, offering improved convenience and sustained glycemic control. Clinical trials demonstrated its efficacy in reducing HbA1c and body weight, along with a low risk of hypoglycemia.

• Liraglutide (Victoza, Saxenda): Liraglutide is a human GLP-1 analogue with a C16 fatty acid chain attached, which allows it to bind to albumin, providing a prolonged half-life suitable for once-daily subcutaneous injection. Approved for T2DM (Victoza) and later for chronic weight management in obese or overweight individuals with comorbidities (Saxenda), liraglutide demonstrated significant HbA1c reduction and modest weight loss. The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial provided landmark evidence of cardiovascular benefit, showing a significant reduction in MACE in T2DM patients with high cardiovascular risk. (ncbi.nlm.nih.gov)

• Dulaglutide (Trulicity): Dulaglutide is a fusion protein consisting of two identical GLP-1 analogues covalently linked to a modified fragment crystallizable (Fc) portion of human immunoglobulin G4 (IgG4). This Fc fusion technology protects the GLP-1 analogue from DPP-4 degradation and reduces renal clearance, enabling once-weekly administration. Dulaglutide has shown robust efficacy in glycemic control and weight reduction. The REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial established its cardiovascular safety and superiority in reducing MACE in patients with T2DM, particularly those with established cardiovascular disease or multiple risk factors. (en.wikipedia.org)

• Semaglutide (Ozempic, Rybelsus, Wegovy): Semaglutide is a highly potent human GLP-1 analogue with a modified amino acid sequence and a C18 fatty diacid linker that allows for strong albumin binding, resulting in an exceptionally long half-life (approximately one week). This enables once-weekly subcutaneous injection for T2DM (Ozempic) and chronic weight management (Wegovy). Semaglutide has demonstrated superior efficacy in reducing HbA1c and body weight compared to other GLP-1 RAs and other diabetes medications in the extensive SUSTAIN and STEP clinical trial programs. Notably, the oral formulation of semaglutide (Rybelsus), utilizing an absorption enhancer (salcaprozate sodium), represents a significant advancement, offering the benefits of a GLP-1 RA in a daily oral pill form. Semaglutide has also demonstrated significant cardiovascular benefits in the SUSTAIN-6 trial. (pubmed.ncbi.nlm.nih.gov)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.2. DPP-4 Inhibitors (Gliptins)

DPP-4 inhibitors prolong the action of endogenous incretin hormones by preventing their enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). By inhibiting this enzyme, they increase the circulating levels of active GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Their efficacy is generally more modest compared to GLP-1 RAs because they rely on the body’s endogenous incretin production, which can be impaired in T2DM.

• Sitagliptin (Januvia): Sitagliptin was the first DPP-4 inhibitor approved for T2DM. It selectively inhibits DPP-4, leading to modest but clinically significant reductions in HbA1c with a low risk of hypoglycemia. The TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) trial demonstrated its cardiovascular safety. (nejm.org)

• Vildagliptin (Galvus): Similar to sitagliptin, vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in T2DM patients. It is typically administered twice daily.

• Saxagliptin (Onglyza): Saxagliptin is another DPP-4 inhibitor, often administered once daily. The SAVOR-TIMI 53 trial showed its cardiovascular safety but observed a slight increase in hospitalization for heart failure in a subgroup of patients, prompting regulatory advisories. (nejm.org)

• Linagliptin (Tradjenta): Linagliptin is unique among DPP-4 inhibitors due to its primary excretion via the enterohepatic system, making it suitable for patients with renal impairment without dose adjustment. The CARMELINA (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin) trial confirmed its cardiovascular and renal safety profile. (nejm.org)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.3. Dual GIP/GLP-1 Receptor Agonists

Recognizing the complementary roles of GIP and GLP-1, and the potential to overcome GIP resistance in T2DM, pharmaceutical research led to the development of single molecules that agonize both GIP and GLP-1 receptors. This ‘twincretin’ approach aims to leverage the full physiological incretin effect.

• Tirzepatide (Mounjaro, Zepbound): Tirzepatide is a groundbreaking dual GIP/GLP-1 receptor agonist. It is a synthetic peptide based on the GIP sequence, modified with a C20 fatty diacid moiety that allows for albumin binding and once-weekly subcutaneous administration. Tirzepatide acts as an agonist at both GIP and GLP-1 receptors, but with a higher affinity for the GIP receptor. This dual agonism leads to synergistic effects on insulin secretion, glucagon suppression, delayed gastric emptying, and appetite regulation. The extensive SURPASS (for T2DM) and SURMOUNT (for obesity) clinical trial programs have demonstrated its superior efficacy in reducing HbA1c and body weight compared to GLP-1 RAs, insulin, and placebo. In SURPASS-2, tirzepatide led to greater HbA1c reductions and weight loss than semaglutide. For obesity, SURMOUNT-1 showed average weight loss exceeding 20% at the highest dose, making it one of the most effective pharmacological agents for weight management to date. It is approved for T2DM (Mounjaro) and for chronic weight management (Zepbound). (pubmed.ncbi.nlm.nih.gov, nejm.org)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.4. Dual GLP-1/Glucagon Receptor Agonists

This class of agents is designed to combine the beneficial effects of GLP-1 agonism (glucose-dependent insulin secretion, glucagon suppression, appetite reduction) with glucagon agonism. While glucagon typically raises blood glucose, its agonism, when balanced with GLP-1, can promote energy expenditure, lipolysis, and satiety through central and peripheral mechanisms. The challenge lies in mitigating glucagon’s hyperglycemic effects while harnessing its metabolic benefits.

• Survodutide (BI 456906): Survodutide is a novel, investigational dual GLP-1/glucagon receptor agonist. It is a peptide designed to provide balanced agonism at both receptors. The GLP-1 component contributes to glycemic control and appetite suppression, while the glucagon component aims to increase energy expenditure, promote lipolysis in adipose tissue, and potentially improve liver fat content. Clinical development has shown promise in significant weight loss and particularly in the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), where the glucagon component may directly impact hepatic fat metabolism. Phase 2 data have demonstrated clinically meaningful weight reduction and substantial improvements in liver fat content and resolution of NASH. (en.wikipedia.org, nejm.org)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.5. Triple Receptor Agonists

Building upon the success of dual agonists, the concept of a single molecule targeting GLP-1, GIP, and glucagon receptors represents the cutting edge of incretin-based therapy. The rationale is to achieve maximal metabolic benefits by integrating the complementary actions of all three hormones: GLP-1 for insulin secretion and appetite suppression, GIP for insulin secretion and fat metabolism, and glucagon for energy expenditure and lipolysis, all within a balanced pharmacological profile.

• Retatrutide (LY3437943): Retatrutide is an investigational GIP, GLP-1, and glucagon receptor triple agonist, administered once weekly. It is a synthetic peptide engineered to activate all three receptors, each contributing to different aspects of metabolic improvement. Preclinical and early clinical data have shown unprecedented efficacy in weight loss and glycemic control. Phase 2 trials demonstrated an average weight reduction of up to 24.2% at the highest dose, marking it as potentially the most effective weight loss medication developed to date. Beyond weight, retatrutide also significantly improves HbA1c, lipid profiles (triglycerides, cholesterol), and blood pressure. Its comprehensive metabolic impact positions it as a potential transformative therapy for both T2DM and obesity, as well as associated comorbidities like NAFLD/NASH. The TRIPLE M program is exploring its full potential across a range of metabolic disorders. (link.springer.com, nejm.org)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3.6. Other Emerging Incretin-Based Therapies

The field continues to evolve rapidly with research into novel combinations and delivery systems:

• Oral Peptides: Further development of oral peptide formulations (like Rybelsus) to improve patient convenience and adherence. Ongoing research aims to enhance bioavailability of larger peptides.
• Amylin Analogs and FGF21: Exploration of incretin agonists combined with other peptides like amylin (e.g., cagrilintide, often in combination with semaglutide as CagriSema) or fibroblast growth factor 21 (FGF21) to achieve even greater metabolic benefits, particularly for weight loss and NAFLD/NASH.
• Small Molecule Agonists: Development of non-peptide small molecule agonists for incretin receptors, potentially offering advantages in oral bioavailability and manufacturing.

4. Clinical Applications

Incretin-based therapies have significantly broadened the therapeutic arsenal for managing T2DM and obesity, offering a more holistic approach to metabolic health.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4.1. Type 2 Diabetes Mellitus

Incretin-based therapies have become cornerstone treatments for T2DM due to their multifaceted benefits:

• Exceptional Glycemic Control: These agents consistently demonstrate significant reductions in HbA1c levels, often surpassing the efficacy of traditional non-insulin agents. GLP-1 RAs and dual/triple agonists not only lower fasting glucose but also effectively manage post-prandial glucose excursions, which are key contributors to overall glycemic burden. The glucose-dependent nature of their insulinotropic effect provides effective glycemic lowering with a low intrinsic risk of hypoglycemia, particularly when used as monotherapy or in combination with medications that do not directly stimulate insulin secretion (e.g., metformin). Furthermore, by preserving and potentially enhancing β-cell function, these therapies offer a disease-modifying effect that may slow the progression of T2DM.

• Substantial Weight Loss: A critical advantage of GLP-1 RAs and particularly multi-receptor agonists is their ability to induce significant and sustained weight loss. This addresses a core component of T2DM pathophysiology, as obesity is the primary risk factor for the disease and exacerbates insulin resistance. By reducing appetite, enhancing satiety, and delaying gastric emptying, these therapies help patients achieve clinically meaningful reductions in body weight, which, in turn, improves insulin sensitivity and overall metabolic health. The weight loss achieved can range from 2-5% for DPP-4 inhibitors to 5-15% for GLP-1 RAs, and even 15-25% or more for dual and triple agonists.

• Cardiovascular Benefits: A pivotal development in the field was the robust demonstration of cardiovascular protective effects by GLP-1 RAs. Large-scale cardiovascular outcome trials (CVOTs) such as LEADER (Liraglutide), SUSTAIN-6 (Semaglutide), REWIND (Dulaglutide), and PIONEER 6 (Oral Semaglutide) consistently showed that GLP-1 RAs reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in T2DM patients with established cardiovascular disease or multiple risk factors. (en.wikipedia.org, nejm.org, nejm.org, nejm.org). The mechanisms underlying these benefits are multifactorial, including improvements in glycemic control, weight loss, blood pressure reduction, lipid profile improvements, anti-inflammatory effects, and direct effects on the endothelium and myocardium.

• Renal Protection: Beyond cardiovascular benefits, GLP-1 RAs have also shown promise in delaying the progression of diabetic kidney disease, particularly by reducing albuminuria (a marker of kidney damage) and preserving kidney function. This renoprotective effect is increasingly recognized as a crucial benefit, complementing other kidney-protective agents.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4.2. Obesity and Weight Management

The profound efficacy of incretin-based therapies in inducing weight loss has led to their approval and widespread use specifically for chronic weight management, marking a transformative shift in the treatment of obesity.

• The Obesity Epidemic: Obesity is a chronic, relapsing disease affecting over a billion people globally, driving a vast array of comorbidities including T2DM, hypertension, dyslipidemia, sleep apnea, certain cancers, and musculoskeletal disorders. Historically, pharmacological options for obesity were limited by modest efficacy and safety concerns, often leaving surgery as the most effective intervention. Incretin-based therapies offer a highly effective medical alternative.

• Mechanism of Action in Obesity: The weight loss effects are primarily mediated through central mechanisms, including direct action on hypothalamic centers regulating appetite and satiety, leading to reduced food intake and decreased cravings. Peripheral mechanisms, such as delayed gastric emptying, also contribute by promoting fullness and reducing the rate of nutrient absorption. The glucagon component in multi-agonists further enhances energy expenditure and lipolysis, contributing to greater fat mass reduction.

• Specific Agents and Clinical Trials:

  • Liraglutide (Saxenda): Approved for weight management in 2014, liraglutide (at a higher dose than for T2DM) demonstrated average weight loss of 5-10% in the SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence in Nondiabetic and Diabetic subjects) trials, significantly improving cardiometabolic risk factors. (nejm.org)
  • Semaglutide (Wegovy): At a higher dose (2.4 mg once weekly), semaglutide was approved for chronic weight management in 2021. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program showed unprecedented weight loss, with patients achieving an average of 15-18% body weight reduction, far exceeding previous pharmacological options. This level of weight loss is often comparable to that seen with bariatric surgery. The significant weight reduction led to improvements in blood pressure, lipids, and other obesity-related complications. (lemonde.fr, nejm.org)
  • Tirzepatide (Zepbound): Approved for obesity in 2023, tirzepatide has shown even greater weight loss efficacy. The SURMOUNT clinical trials demonstrated average weight reductions ranging from 15% to over 22% at the highest doses. Its superior efficacy is attributed to the synergistic actions of GIP and GLP-1 agonism, making it a highly impactful treatment for individuals living with obesity. (pubmed.ncbi.nlm.nih.gov, nejm.org)
  • Retatrutide: Early clinical data suggest retatrutide may push the boundaries further, with reported average weight loss exceeding 24%, setting a new benchmark for pharmacological weight management. (nejm.org)

These therapies are revolutionizing obesity care, offering non-surgical options that can achieve substantial and clinically meaningful weight loss, improving health outcomes and quality of life for millions.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4.3. Other Potential Applications

The broad physiological effects of incretins suggest potential therapeutic roles beyond T2DM and obesity:

• Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): Given the strong link between obesity, T2DM, and liver steatosis, incretin-based therapies, particularly those with glucagon agonism (e.g., survodutide, retatrutide), are being actively investigated for their ability to reduce liver fat, inflammation, and fibrosis in NAFLD/NASH. Early results are highly promising.
• Polycystic Ovary Syndrome (PCOS): As PCOS is often associated with insulin resistance and obesity, incretin therapies may offer benefits by improving metabolic parameters and aiding weight loss in affected individuals.
• Neurodegenerative Diseases: Preclinical studies suggest GLP-1 receptors are expressed in the brain and GLP-1 RAs may have neuroprotective properties, potentially offering therapeutic avenues for conditions like Alzheimer’s and Parkinson’s disease. Clinical trials are currently exploring this fascinating area.

5. Efficacy and Safety Profiles

The efficacy and safety of incretin-based therapies are well-documented, with distinct profiles across the different drug classes. While generally well-tolerated, understanding their side effects and contraindications is crucial for optimal patient management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5.1. Common Side Effects

The most frequently reported side effects for GLP-1 RAs, dual, and triple agonists are gastrointestinal in nature, typically mild to moderate in severity, and tend to be transient, often improving with continued treatment or dose titration.

• Gastrointestinal Discomfort: Nausea, vomiting, diarrhea, and constipation are common. These symptoms are primarily related to the delayed gastric emptying effect and direct effects on gut motility, as well as potential central nervous system effects on the chemoreceptor trigger zone. Slow dose escalation (titration) is a key strategy to mitigate these side effects, allowing the body to adapt to the medication. Patients are often counselled to eat smaller meals, avoid high-fat foods, and remain hydrated.

• Hypoglycemia: The risk of hypoglycemia is low with GLP-1 RAs and multi-agonists when used as monotherapy or in combination with medications that do not independently cause hypoglycemia (e.g., metformin, SGLT2 inhibitors). This is due to their glucose-dependent mechanism of action. However, the risk increases when these agents are combined with insulin or sulfonylureas, necessitating careful monitoring and potential dose adjustment of the concomitant medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5.2. Less Common / Rare Side Effects

While generally safe, certain less common or rare adverse events require consideration:

• Pancreatitis: An initial concern with incretin-based therapies was a potential link to acute pancreatitis. Extensive post-marketing surveillance and large-scale meta-analyses have largely not shown a significantly increased risk of acute pancreatitis compared to other diabetes medications, or the observed risk is very low. However, patients with a history of pancreatitis should be approached with caution, and these medications should be discontinued if acute pancreatitis is suspected. (diabetesjournals.org)

• Thyroid C-cell Tumors / Medullary Thyroid Carcinoma (MTC): In rodent studies, GLP-1 RAs have been associated with an increased incidence of thyroid C-cell tumors. The clinical relevance of this finding in humans remains unclear, as human thyroid C-cells express few GLP-1 receptors and data from long-term clinical trials have not established a causal link. Nevertheless, GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

• Gallbladder Disease (Cholelithiasis/Cholecystitis): Emerging evidence, particularly from large-scale obesity trials with significant and rapid weight loss, suggests an increased risk of cholelithiasis (gallstones) and subsequent cholecystitis (gallbladder inflammation) with GLP-1 RAs and multi-agonists. This risk is likely associated with the rapid weight loss itself, which can alter bile composition, rather than a direct drug effect. Patients experiencing severe abdominal pain should be evaluated for gallbladder issues.

• Acute Kidney Injury: Although GLP-1 RAs have shown renoprotective benefits, there have been rare reports of acute kidney injury, particularly in patients who experience severe gastrointestinal side effects (e.g., dehydration from vomiting/diarrhea) or those with pre-existing renal impairment. Adequate hydration and careful monitoring of renal function, especially during initiation or dose escalation, are important.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5.3. Comparative Efficacy and Safety

• DPP-4 Inhibitors: Offer mild to moderate glycemic efficacy with a very favorable safety profile, minimal GI side effects, and no weight effects (neutral). They are suitable for patients needing modest glycemic improvement or those intolerant to other agents.

• GLP-1 Receptor Agonists: Provide high glycemic efficacy, significant weight loss, and proven cardiovascular and renal benefits. Common GI side effects are manageable with titration. They are a preferred choice for T2DM patients with or at high risk of cardiovascular disease, kidney disease, or those needing weight reduction.

• Dual and Triple Agonists (e.g., Tirzepatide, Retatrutide): Demonstrate superior efficacy in both glycemic control and weight loss compared to GLP-1 RAs. The incidence of gastrointestinal side effects may be slightly higher or similar, but generally manageable. Their extensive weight loss capabilities make them particularly impactful for individuals with obesity, with or without T2DM. Long-term safety data, particularly for triple agonists, are still accumulating, but current profiles are consistent with established incretin therapies. (link.springer.com)

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5.4. Patient Selection and Contraindications

The choice of incretin-based therapy depends on individual patient characteristics, clinical goals, comorbidities, and preferences. Factors to consider include: HbA1c target, desired weight loss, presence of cardiovascular or renal disease, history of pancreatitis or MTC, patient tolerance to side effects, administration route preference (injectable vs. oral), and cost.

Absolute contraindications include a personal or family history of MTC or MEN2 for GLP-1 RAs and multi-agonists. Severe gastrointestinal disease (e.g., gastroparesis) should be considered a relative contraindication due to potential exacerbation of symptoms. Pregnancy and breastfeeding are generally contraindications due to lack of sufficient safety data.

6. Future Directions

The field of incretin-based therapies is a dynamic area of research, with ongoing efforts to further enhance efficacy, improve safety, and expand their therapeutic utility.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6.1. Next-Generation Agonists and Combinations

Research is focused on developing even more potent and selective multi-agonists, potentially combining GLP-1, GIP, and glucagon agonism with other metabolic pathways. Novel agents are exploring co-agonism with amylin (e.g., cagrilintide, often combined with semaglutide in CagriSema) for enhanced satiety and weight loss, or fibroblast growth factor 21 (FGF21) to target lipid metabolism and liver steatosis. The aim is to create ‘designer’ peptides that can achieve unprecedented levels of metabolic control and weight reduction by orchestrating multiple physiological pathways simultaneously. Furthermore, efforts are underway to develop oral peptide formulations with improved bioavailability and small molecule agonists that could offer greater convenience and potentially lower manufacturing costs.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6.2. Personalized Medicine and Biomarkers

As the armamentarium of incretin-based therapies expands, identifying which patients will respond best to specific agents becomes crucial. Future research will focus on developing biomarkers (genetic, proteomic, or metabolic) that can predict individual patient responses to GLP-1 RAs, dual, or triple agonists. This will enable a truly personalized approach, optimizing treatment selection from the outset and moving beyond a ‘trial and error’ approach. Artificial intelligence and machine learning are poised to play a significant role in analyzing vast datasets to identify these predictive markers and guide precision prescribing.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6.3. Expansion into New Indications

The remarkable efficacy of incretin-based therapies suggests their potential utility beyond current indications:

• Primary Prevention of T2DM: Given their ability to induce significant weight loss and improve insulin sensitivity, these therapies could be instrumental in preventing the onset of T2DM in high-risk individuals.
• Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): As highlighted, current investigations are showing strong promise, especially for agents with a glucagon component, in directly addressing hepatic steatosis and inflammation, potentially becoming first-line treatments for these common liver diseases.
• Heart Failure with Preserved Ejection Fraction (HFpEF): Emerging data suggest a potential role for GLP-1 RAs in patients with HFpEF, often associated with obesity and T2DM, by improving cardiac function and exercise capacity. (nejm.org)
• Neuroprotection and Cognitive Function: Preclinical studies exploring GLP-1 RAs for their anti-inflammatory and neurotrophic effects in neurodegenerative diseases like Alzheimer’s and Parkinson’s continue, with several clinical trials underway. These therapies could potentially slow disease progression or improve cognitive function in affected individuals.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6.4. Accessibility and Affordability

The high cost of novel incretin-based therapies presents a significant challenge to their widespread adoption and accessibility, particularly in resource-limited settings. Future efforts will need to address strategies for cost reduction, including the development of biosimilars, and advocate for broader insurance coverage to ensure that these life-changing treatments are available to all who could benefit.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6.5. Long-Term Safety and Efficacy

While current data for GLP-1 RAs demonstrate excellent long-term safety and sustained efficacy, continued monitoring is essential, particularly for the newer dual and triple agonists. Long-term studies will be crucial to fully characterize the durability of weight loss and glycemic control, as well as to detect any rare or delayed adverse events. Understanding the impact on patient-reported outcomes and overall quality of life over extended periods will also be vital.

7. Conclusion

Incretin-based therapies represent one of the most significant advancements in metabolic medicine of the 21st century. From the initial discovery of GLP-1 and GIP to the development of highly effective multi-receptor agonists, this therapeutic class has transformed the management of type 2 diabetes and obesity. These agents offer a powerful combination of robust glycemic control, profound and sustained weight loss, and established cardiovascular and renal protection, moving beyond symptomatic treatment to address the underlying pathophysiology of these complex chronic diseases.

The journey from single-receptor GLP-1 agonism to dual GIP/GLP-1 agonism and now triple GIP/GLP-1/glucagon agonism exemplifies the rapid pace of innovation. With tirzepatide and retatrutide setting new benchmarks for efficacy, the future holds promise for further optimization through next-generation molecules, personalized treatment strategies, and expansion into novel indications such as NAFLD/NASH and neurodegenerative disorders. While challenges related to accessibility and long-term safety monitoring persist, the transformative impact of incretin-based therapies on human health is undeniable, offering renewed hope and significantly improved outcomes for millions of individuals living with metabolic disease.

References

• pubmed.ncbi.nlm.nih.gov
• en.wikipedia.org
• link.springer.com
• en.wikipedia.org
• lemonde.fr
• ncbi.nlm.nih.gov – Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. (LEADER trial)
• nejm.org – Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-242. (TECOS trial)
• nejm.org – Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-1326. (SAVOR-TIMI 53 trial)
• nejm.org – Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. (CARMELINA trial)
• nejm.org – Jastreboff AM, Natarajan N, Bruck H, et al. Tirzepatide Once Weekly for the Treatment of Obesity and Overweight: A Phase 3 Study. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1 trial)
• nejm.org – D. K. W. Chow, S. M. C. Lim, S. N. C. Lau, et al. A Phase 2 Trial of Survodutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024;390(19):1758-1769.
• nejm.org – Jastreboff AM, Greig AJ, Ma X, et al. Triple-Hormone-Receptor Agonist Retatrutide for Type 2 Diabetes: A Phase 2 Randomized Trial. N Engl J Med. 2023;389(13):1127-1139.
• diabetesjournals.org – Dicembrini I, Nannipieri M, Barbieri M, et al. Incretin-Based Drugs and the Risk of Pancreatitis: A Systematic Review and Meta-analysis. Diabetes Care. 2014;37(4):1199-1210.
• nejm.org – Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN-6 trial)
• nejm.org – Hernandez AF, Green JB, Holmes DN, et al. Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): a double-blind, randomised, placebo-controlled trial. Lancet. 2018;392(10156):1519-1529.
• nejm.org – Husain M, Bain SC, Holst AG, et al. Cardiovascular and Renal Outcomes With Dulaglutide in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: The REWIND Trial. Lancet. 2019;394(10212):1807-1817. (REWIND trial)
• nejm.org – Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. (SCALE Obesity and Prediabetes trial)
• nejm.org – Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1 trial)
• nejm.org – Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1 trial)
• nejm.org – Kosiborod MN, Abildgaard U, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1081.